Canton Strategic Holdings, Inc. (Nasdaq: CNTN) is a Red Bank, New Jersey company focused on institutional blockchain adoption and the digitization of financial markets. It runs a Canton Coin digital asset treasury and operates a Super Validator node on the Canton Network, and it sells a locking service that helps other network infrastructure providers meet their Canton Coin commitment requirements. The company was formerly Tharimmune, Inc. and took its current name in February 2026; alongside the digital asset business it ran a clinical-stage biotechnology segment (GV104, a nalmefene buccal film for respiratory depression, and GV023, an oral anti-TNF-alpha antibody) until selling Gravitas Life Sciences, LLC in July 2026 to concentrate on its Canton Network strategy. CEO Mark Wendland, previously Partner and COO at DRW and a treasury leader at Citadel, was elected to the Canton Foundation board in March 2026.